Axalbion Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $14.4M

  • Investors
  • 3

Axalbion General Information

Description

Developer of molecular transducer-based therapies designed to create a safe drug for the treatment of chronic cough. The company's therapies are based on new transducer agonists, identifying two lead candidates, and also offer topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes, as well as by decreasing sensory discomfort, enabling doctors to provide targeted treatment options.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Medicines Evaluation Unit, The Langley Building
  • Southmoor Road, Wythenshawe
  • Manchester M23 9QZ
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Medicines Evaluation Unit, The Langley Building
  • Southmoor Road, Wythenshawe
  • Manchester M23 9QZ
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axalbion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 01-Apr-2024 $14.4M Completed Clinical Trials - Phase 2
4. Later Stage VC 07-Feb-2022 Completed Clinical Trials - Phase 2
3. Secondary Transaction - Private 01-May-2021 Completed Clinical Trials - Phase 2
2. Early Stage VC 06-Jul-2018 $1.01M Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Startup
To view Axalbion’s complete valuation and funding history, request access »

Axalbion Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary
A Ordinary
A Ordinary 887,900 $14.61 $14.61 1x $14.61 34.76%
Ordinary 219,318 $9.79 $9.79 2x $9.79 8.59%
To view Axalbion’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Axalbion Patents

Axalbion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2973546-T3 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for the treatment of chronic cough Active 10-Jun-2019
AU-2020293622-A1 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough Active 10-Jun-2019
AU-2020293622-B2 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough Active 10-Jun-2019
AU-2025205040-A1 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough Inactive 10-Jun-2019
CA-3143094-A1 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough Active 10-Jun-2019 A61K31/223
To view Axalbion’s complete patent history, request access »

Axalbion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axalbion Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Moulton Goodies Venture Capital Minority
Perscitus Family Office Minority
EPFL Innovation Park Accelerator/Incubator Minority
To view Axalbion’s complete investors history, request access »

Axalbion FAQs

  • When was Axalbion founded?

    Axalbion was founded in 2016.

  • Where is Axalbion headquartered?

    Axalbion is headquartered in Manchester, United Kingdom.

  • What is the size of Axalbion?

    Axalbion has 6 total employees.

  • What industry is Axalbion in?

    Axalbion’s primary industry is Drug Discovery.

  • Is Axalbion a private or public company?

    Axalbion is a Private company.

  • What is the current valuation of Axalbion?

    The current valuation of Axalbion is .

  • What is Axalbion’s current revenue?

    The current revenue for Axalbion is .

  • How much funding has Axalbion raised over time?

    Axalbion has raised $17.7M.

  • Who are Axalbion’s investors?

    Moulton Goodies, Perscitus, and EPFL Innovation Park have invested in Axalbion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process